A COL4A3 gene mutation and post-transplant anti-a3(IV) collagen alloantibodies in Alport syndrome. The X-Iinked Alport syndrome is associated with mutations and deletions in COL4A5 gene, one of six genes which constitute the ^-chains of type IV collagen in basement membranes. The autosomal recessive form of Alport syndrome is characterized by mutations and deletions in the COL4A3 and COL4A4 genes. A fraction of Alport patients who undergo renal transplantation develop anti-glomerular basement membrane (GBM) nephritis, which results in loss of the renal allograft function. Recently, the target for alloantibodies from an X-linked Alport patient with complete COL4A5 gene deletion was determined to be the a3 chain of type IV collagen. The present study characterized the post-transplant alloantibodies from an autosomal reces sive Alport patient with anti-GBM glomerulonephritis and a COL4A3 gene mutation which predicted a loss of 85% of the a3(IV) NCI domain. The specificity of these new antibodies were studied using glomerular basement membrane constituents and recombinant type IV collagen domains. The results establish the target for the alloantibodies, from an autosomal recessive Alport patient with COL4A3 deletion as principally the c y 3(IV) collagen chain, similar to the post-transplant alloantibodies from X-linked Alport patients with COL4A5 gene deletions, The absence of c y 3(IV) chain in the GBM of patients with both these forms of Alport syndrome, due either to a failure of synthesis or a failure of assembly, presumably leads to a loss of immunologic tolerance for the a3(IV) NCI domain in transplanted allografts.
« . upon incubation with the circulating alloantibodies (Fig. IB) . These results suggest that additional binding sites for the alloantisera in the transplanted kidney are accessible in vitro compared to in vivo, and that there is a structural difference within the GBM of the Alport and transplanted kidney.
Specificity o f alloantibodies to GBM constituents and bovine type IV collagen domains
The specificity of post-transplant anti-GBM alloantibodies from an autosomal recessive Alport patient with COL4A3 deletion was determined using bovine GBM constituents and bovine NCI domains of the a-chains of type IV collagen. The GBM constit uents used were: fibronectin, Iaminin, heparan sulfate proteogly can and entactin. Bovine type IV collagen domains used were: 7 S domain of type IV collagen, pepsin solubilized triple helical fragments of type IV collagen and dimeric and monomeric NCI domains of type IV collagen a-chains. The alloantibodies reacted specifically to the a3(IV) NCI containing dimers and a3(IV) NCI monomers (Fig. 2) .
Specificity o f the alloantibodies to bovine type IV collagen NCI domains by one-and two-dimensional gel electrophoresis and immunoblotting
The alloantibodies from the affected patient were analyzed by one-and two-dimensional gel electrophoresis and immunoblot ting with the bovine NCI hexamer, bovine a l + a2 NCI dimers r Dinners
yys. 
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Inhibition ELISA
Type IV collagen a-chain specific antibodies were used to perform inhibition ELISA using bovine NCI hexamer as the antigen. The NCI hexamer was allowed to bind with one of the six a-chain specific antibodies and subsequently followed with the Alport alloantibodies. The anti-a3(IV) chain specific antibodies inhibited the alloantibodies binding ( Figs. 4 A and B ). All the other antibodies did not inhibit the alloantibodies binding to the NCI hexamer. These results establish the alloantibodies as anti-a3(IV)NCl antibodies.
Specificity o f the alloantibodies to the recombinant human type IV collagen NCI domains
The alloantibodies were further analyzed for their capacity to bind recombinant human type IV collagen NCI domains (al to a5). The alloantibodies reacted very strongly to the recombinant a3(IV) NCI ( Fig. 5 
) and to a very minor degree with the recombinant a5(lV)NCl domain (1:200 dilution of alloantisera, lost at 1:500). The weak reactivity with the a5(IV)NCl may be a cross-reactivity phenomenon, due to the high homology between the NCI domains [24]. Alternatively, the weak binding may be specific reactivity only observed with human a5(IV)NCl se quence; repeating the gel with half the amount of target NCI domains eliminated evidence of weak binding while preserving the strong reactivity to a3. These results establish the principal target for post-transplant anti-GBM nephritis in an Alport patient with COL4A3 gene deletion as the a3 chain of type IV collagen.
Discussion
In several previous studies, the target for X-linked Alport alloantibodies was identified as the NCI domain of type IV collagen 
